Gefitinib is a type of targeted cancer drug called a tyrosine kinase inhibitor (TKI). Tyrosine kinases. are proteins that sends signals telling cancer cells to grow. Gefitinib bocks these signals. For gefitinib to work the cancer cells need to have receptors for a protein called epidermal growth factor.
Gefitinib
Medication
Gefitinib, sold under the brand name Iressa, is a medication used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor in target cells. Wikipedia
Molar mass: 446.902 g/mol
AHFS/Drugs.com: Monograph
ATC code: L01EB01 (WHO)
Bioavailability: 59% (oral)
Elimination half-life: 6–49 hours
Other names: ZD1839
Pregnancy category: AU: C
People also ask
Is gefitinib a chemotherapy?
Why was gefitinib taken off the market?
What is the drug gefitinib used for?
Is gefitinib an EGFR inhibitor?
Dec 15, 2015 · Gefitinib is used to treat non-small cell lung cancer that has spread to other parts of the body in people with certain types of tumors.
Gefitinib, sold under the brand name Iressa, is a medication used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib ...
Gefitinib is a tyrosine kinase inhibitor used as first-line therapy to treat non-small cell lung carcinoma (NSCLC) that meets certain genetic mutation criteria.
Gefitinib (ZD1839) is an orally active selective inhibitor of epidermal growth factor receptor tyrosine kinase, an enzyme that regulates intracellular ...
A drug used to treat non-small cell lung cancer that has spread to other parts of the body and has certain mutations (changes) in the EGFR gene.
Gefitinib is a selective tyrosine kinase receptor inhibitor used in the therapy of non-small cell lung cancer. Gefitinib therapy is associated with transient ...
Medscape - Non-small cell lung cancer indication dosing for Iressa (gefitinib), frequency-based adverse effects, comprehensive interactions, ...
Gefitinib (Iressa®) is a drug used in the treatment of locally advanced or metastatic NSCLC. Gefitinib belongs to a class of TKIs that compete with ATP for its ...
Related searches
Related health topics
For informational purposes only. Consult your local medical authority for advice.